Compare LAND & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAND | MYGN |
|---|---|---|
| Founded | 1997 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.1M | 372.1M |
| IPO Year | 2010 | 1996 |
| Metric | LAND | MYGN |
|---|---|---|
| Price | $8.88 | $5.82 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $9.33 | $4.11 |
| AVG Volume (30 Days) | 514.6K | ★ 2.7M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 6.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $88,339,000.00 | ★ $771,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | $5.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.66 | 2.33 |
| 52 Week Low | $7.92 | $2.74 |
| 52 Week High | $13.00 | $8.50 |
| Indicator | LAND | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 74.13 |
| Support Level | $7.95 | $5.57 |
| Resistance Level | $8.90 | $6.34 |
| Average True Range (ATR) | 0.27 | 0.33 |
| MACD | -0.10 | 0.16 |
| Stochastic Oscillator | 25.48 | 92.25 |
Gladstone Land Corp is an externally-managed, agricultural REIT. It is mainly in the business of owning and leasing farmland. It manages operations in one reporting segment: Real Estate Rental Operations. It is focused on the ownership of farms and farm-related properties that are leased on a triple-net basis to tenants with a good operating history and deep farming resources. The farmland is predominantly concentrated in locations where farmers are able to grow either fresh produce or annual row crops (e.g., certain berries and vegetables), which are typically planted and harvested annually, or certain permanent crops (e.g., almonds, blueberries, pistachios, and wine grapes). To a much lesser extent, it also owns farms that grow certain commodity crops (e.g., corn and beans).
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.